Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13DFiled 27 h ago

ANAPTYSBIO, INC: EcoR1 Capital, LLC amends Schedule 13D stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13D, sec.gov, 19 November 2026, by SEC EDGAR SCHEDULE 13D

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

EcoR1 Capital, LLC amended its Schedule 13D stake filing for AnaptysBio, Inc., according to SEC accession 0000935836-26-000634. The filing updates the fund's previously reported beneficial ownership position in the clinical-stage biotech. Schedule 13D amendments are required when an investor's ownership or intent changes materially, making the disclosure a signal of activist or strategic interest. Investors should watch for the specific share count and percentage disclosed, plus any language on board seats, strategic alternatives or further purchases.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.

Named in this story

AnaptysBio, Inc., EcoR1 Capital, LLC